litlas
Log inCreate account

Jonathan W. Friedberg

Active 1995–2025

Also published as
Jonathan W Friedberg
142
Papers
26,693
Citations
81
h-index
135
i10-index

Citations

Citations per year for Jonathan W. Friedberg1978: 1 citations1986: 1 citations1992: 1 citations1998: 1 citations1999: 1 citations2000: 4 citations2001: 8 citations2002: 4 citations2003: 18 citations2004: 24 citations2005: 41 citations2006: 44 citations2007: 49 citations2008: 45 citations2009: 54 citations2010: 65 citations2011: 80 citations2012: 96 citations2013: 103 citations2014: 89 citations2015: 133 citations2016: 120 citations2017: 172 citations2018: 242 citations2019: 910 citations2020: 1,096 citations2021: 1,103 citations2022: 956 citations2023: 753 citations2024: 1,337 citations2025: 607 citations2026: 10 citations1979–1985: no citations, so these years are not shown1987–1991: no citations, so these years are not shown1993–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,400 citing papers, 29.6% of this breakdownChina: 1,006 citing papers, 8.8% of this breakdownGermany: 719 citing papers, 6.3% of this breakdownUnited Kingdom: 652 citing papers, 5.7% of this breakdownFrance: 620 citing papers, 5.4% of this breakdownItaly: 614 citing papers, 5.3% of this breakdownSpain: 450 citing papers, 3.9% of this breakdownCanada: 427 citing papers, 3.7% of this breakdownSwitzerland: 356 citing papers, 3.1% of this breakdownAustralia: 298 citing papers, 2.6% of this breakdownNetherlands: 290 citing papers, 2.5% of this breakdownJapan: 247 citing papers, 2.1% of this breakdown
0%29.6%Other 21%

Institutions

Fields

  • Medicine86.1%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Immunology and Microbiology5.3%
  • Engineering0.4%
  • Computer Science0.3%
  • Materials Science0.2%
  • Other1%

Topics

  • CAR-T cell therapy research16.8%
  • Lymphoma Diagnosis and Treatment13.7%
  • Chronic Lymphocytic Leukemia Research4.2%
  • Immune Cell Function and Interaction4.1%
  • Virus-based gene therapy research3.9%
  • CNS Lymphoma Diagnosis and Treatment3.3%
  • Other54%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 cited by 5,915

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: Elı́as Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Doǧan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesús F. San Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana H. Advani, Stephen M. Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  3. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    Authors: Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 cited by 843

  4. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

    Authors: Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Długosz‐Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana H. Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon‐Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus - New England Journal of Medicine 2022 cited by 328

  5. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

    Authors: James N. Kochenderfer, Robert Somerville, Tangying Lu, Victoria Shi, Adrian Bot, John M. Rossi, Allen Xue, Stephanie L. Goff, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Marika Sherman, Arianne Perez, Constance M. Yuan, Tatyana Feldman, Jonathan W. Friedberg, Mark Roschewski, Steven A. Feldman, Lori McIntyre, Mary Ann Toomey, Steven A. Rosenberg - Journal of Clinical Oncology 2017 cited by 561

  6. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Authors: Carla Casulo, Michelle Byrtek, Keith Dawson, Xiaolei Zhou, Charles M. Farber, Christopher R. Flowers, John D. Hainsworth, Matthew J. Maurer, James R. Cerhan, Brian K. Link, Andrew D. Zelenetz, Jonathan W. Friedberg - Journal of Clinical Oncology 2015 cited by 844

  7. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Authors: Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski and 69 more - The Lancet 2018 cited by 726

  8. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Authors: Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi Pederson, Mei‐Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner‐Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha Reddy, Jane N. Winter, Julie Chang, Ajay K. Gopal, Amy Chadburn, Susan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schöder, Andrew D. Zelenetz, John P. Leonard - Journal of Clinical Oncology 2019 cited by 423

  9. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Authors: Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby‐Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria Alma Rodriguez, Auayporn Nademanee, Mark Kaminski, Myron S. Czuczman, Michael Millenson, Joyce C. Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter - Blood 2013 cited by 953

  10. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

    Authors: Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens, Kelly Davison, Angela Punnett, David Hodgson, Susan K. Parsons, Sairah Ahmed, Carla Casulo, Nancy L. Bartlett, Joo Y. Song, Richard F. Little, Brad S. Kahl, John P. Leonard, Kara M. Kelly, Sonali M. Smith, Jonathan W. Friedberg - Journal of Clinical Oncology 2023 cited by 117

  11. Classical Hodgkin lymphoma

    Authors: Pauline Brice, Eric de Kerviler, Jonathan W Friedberg - The Lancet 2021 cited by 162

  12. Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Authors: Jonathan W. Friedberg - Hematology 2011 cited by 502

  13. Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

    Authors: Sven de Vos, John P. Leonard, Jonathan W. Friedberg, Jasmine Zain, Kieron Dunleavy, Rod Humerickhouse, John Hayslip, John C. Pesko, Wyndham H. Wilson - Leukemia & lymphoma/Leukemia and lymphoma 2020 cited by 93

  14. Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

    Authors: Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens, Kelly Davison, Angela Punnett, Susan K. Parsons, Sairah Ahmed, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Matthew Mei, Brian Hess, Ryan Jacobs, Hayder Saeed, Pallawi Torka, Boyu Hu, Craig H. Moskowitz, Supreet Kaur, Gaurav Goyal, Christopher J. Forlenza, Andrew Doan, Adam J. Lamble, Pankaj Kumar, Saeeda Chowdhury, Brett T. Brinker, Namita Sharma, Avina K. Singh, Kristie A. Blum, Anamarija M. Perry, Alexandra E. Kovach, David Hodgson, Louis S. Constine, Lale Kostakoglu Shields, Anca Prica, Hildy Dillon, Richard F. Little, Margaret A. Shipp, Michael Crump, Brad S. Kahl, John P. Leonard, Sonali M. Smith, Joo Y. Song, Kara M. Kelly, Jonathan W. Friedberg - New England Journal of Medicine 2024 cited by 200

  15. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

    Authors: Kieron Dunleavy, Michelle A. Fanale, Jeremy S Abramson, Ariela Noy, Paolo F. Caimi, Stefania Pittaluga, Samir Parekh, Ann S. LaCasce, John W. Hayslip, Deepa Jagadeesh, Sunil Nagpal, Mary Jo Lechowicz, Rakesh Gaur, Andrea N. Lucas, Christopher Melani, Mark Roschewski, Seth M. Steinberg, Elaine S. Jaffe, Brad S. Kahl, Jonathan W. Friedberg, Richard F. Little, Nancy L. Bartlett, Wyndham H. Wilson - The Lancet Haematology 2018 cited by 232

  16. In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

    Authors: Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, Leo I. Gordon, Jonathan W. Friedberg, Debra K. Czerwinski, Steven Long, Richard T. Hoppe, Robert S. Janssen, Albert F. Candia, Robert L. Coffman, Ronald Levy - Cancer Discovery 2018 cited by 188

  17. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

    Authors: Vindi Jurinović, Robert Kridel, Annette M. Staiger, Monika Szczepanowski, Heike Horn, Martin Dreyling, Andreas Rosenwald, German Ott, Wolfgang Hiddemann, Andrew D. Zelenetz, Paul M. Barr, Jonathan W. Friedberg, Stephen M. Ansell, Laurie H. Sehn, Joseph M. Connors, Randy D. Gascoyne, Wolfgang Hiddemann, Michael Unterhalt, David M. Weinstock, Oliver Weigert - Blood 2016 cited by 229

  18. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

    Authors: Nina D. Wagner‐Johnston, Brian K. Link, Michelle Byrtek, Keith Dawson, John D. Hainsworth, Christopher R. Flowers, Jonathan W. Friedberg, Nancy L. Bartlett - Blood 2015 cited by 218

  19. Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

    Authors: Brian K. Link, Bann‐Mo Day, Xiaolei Zhou, Andrew D. Zelenetz, Keith Dawson, James R. Cerhan, Christopher R. Flowers, Jonathan W. Friedberg - British Journal of Haematology 2018 cited by 97

  20. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

    Authors: Mark Roschewski, Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel, Philip J. Bierman, Deepa Jagadeesh, Ronald T. Mitsuyasu, David Peace, Peter R. Watson, Wahid T. Hanna, Christopher Melani, Andrea N. Lucas, Seth M. Steinberg, Stefania Pittaluga, Elaine S. Jaffe, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Michelle A. Fanale, Ariela Noy, Wyndham H. Wilson - Journal of Clinical Oncology 2020 cited by 150

  21. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

    Authors: Heiko Schöder, Mei‐Yin C. Polley, Michael V. Knopp, Nathan C. Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary J. Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina D. Wagner‐Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett - Blood 2020 cited by 94

  22. Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

    Authors: Daniel O. Persky, Hongli Li, Deborah M. Stephens, Steven I. Park, Nancy L. Bartlett, Lode J. Swinnen, Paul M. Barr, Jerome D. Winegarden, Louis S. Constine, Thomas J. FitzGerald, John P. Leonard, Brad S. Kahl, Michael LeBlanc, Joo Y. Song, Richard I. Fisher, Lisa M. Rimsza, Sonali M. Smith, Thomas P. Miller, Jonathan W. Friedberg - Journal of Clinical Oncology 2020 cited by 128

  23. Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells

    Authors: Andrew G. Evans, Paul G. Rothberg, Richard Burack, Scott F. Huntington, David L. Porter, Jonathan W. Friedberg, Jane L. Liesveld - British Journal of Haematology 2015 cited by 105

  24. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

    Authors: Leo I. Gordon, Fangxin Hong, Richard I. Fisher, Nancy L. Bartlett, Joseph M. Connors, Randy D. Gascoyne, Henry Wagner, Patrick J. Stiff, Bruce D. Cheson, Mary Gospodarowicz, Ranjana H. Advani, Brad S. Kahl, Jonathan W. Friedberg, Kristie A. Blum, Thomas M. Habermann, Joseph M. Tuscano, Richard T. Hoppe, Sandra J. Horning - Journal of Clinical Oncology 2012 cited by 309